You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Julia Karow tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb. Follow her on Twitter at @Julia_Karow.
At an AMP virtual meeting workshop, a Mayo Clinic lab director offered advice on what diseases to include, how to handle VUSs, and other considerations for ECS.
The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.
During a session at the ASHG 2020 virtual meeting, representatives from both organizations laid out the reasons for their contrasting guidelines.
The firm reported $2 billion in third-quarter revenues related to the COVID-19 response, accounting for 23 percent of its overall revenues.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
A clinical evaluation of LamPore, expected to be CE marked shortly, called it promising for high-throughput testing but recommended a more streamlined workflow.
The startup wants to serve the 50 percent or so of genetic disease patients who haven't obtained a molecular diagnosis despite extensive testing.
Germany's Federal Ministry of Health issued an order last Friday making testing freely available to returning travelers within 72 hours of entering the country.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
The firm saw revenues grow 10 percent in Q2, in part driven by PCR-based COVID-19 testing, as it increased production capacity to 10 million tests per week.